Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald Initiates Tourmaline Bio(TRML.US) With Buy Rating
Guggenheim Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Tourmaline Bio (TRML) Receives a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Tourmaline Bio (TRML), Amicus (FOLD) and Kura Oncology (KURA)
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $15
Tourmaline Bio Analyst Ratings
Buy Rating Affirmed for Tourmaline Bio Amid Promising Clinical Trials and Strong Market Potential
Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)
Tourmaline Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)
Tourmaline Bio Analyst Ratings
Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)
Maintaining Buy Rating on Tourmaline Bio Amid Strong Clinical Progress and Financial Stability
Tourmaline Bio Analyst Ratings
Buy Rating Affirmed for Tourmaline Bio Amidst Promising Clinical Trials and Drug Candidate Prospects